Phase III Data: Amyloid Agent Falls Short for AD

Tramiprosate, the first antiamyloid drug to enter a phase III trial, was not significantly better than placebo in improving cognitive function in patients with Alzheimer disease, according to officials of Neurochem Inc., manufacturer of the investigational agent and sponsor of the North American trial.